Michel L. Tremblay


Affiliation : Université McGill
Organization : Rosalind and Morris Goodman Cancer Centre
E-mail : michel.tremblay@mcgill.ca



About Michel L. Tremblay


Michel L. Tremblay obtained his PhD from McMaster University. Fellow of the National Cancer Institute of Canada, he pursued his training at the National Institute of Health (USA) in order to establish the new technology of gene targeting using embryonic stem cells. He was a key contributor in the generation of the first functional animal model of a human disease ever generated by gene targeting (Gaucher’s disease). In 1992, he became assistant professor in the department of Biochemistry at McGill University. During this period, he cloned several novel protein tyrosine phosphatases (PTP) genes involved in various human diseases including cancer. Professor Tremblay’s laboratory published several papers on the initial characterization of these PTP genes and in 1999 with Merck Frosst, a milestone study in the journal Science on the first PTPase modulator of the Insulin Receptor. In 2007, he was named personality of the week in La Presse for his research on breast cancer. This work was also selected by Québec Science magazine as the top scientific discovery of that year. Professor Tremblay is recognized internationally in the field of PTPs. Director of the Goodman Cancer Research Centre since July 2000, he initiated the foundation of two biotech companies based on his expertise and new discoveries, and pursued various research projects in partnership with the biotech/pharma industry. He was nominated as member of the FRSQ Executive Board, honoured as the Jeanne and Jean–Louis Lévesque Chair in Cancer Research and also as a James McGill Chair. He is a Fellow to the Academy of Sciences of the Royal Society of Canada.

Ongoing competitions